Xarelto

Chemical Namerivaroxaban
Dosage FormTablet (oral; 2.5 mg, 10 mg, 15 mg, 20 mg); Suspension (oral; 1 mg/mL)
Drug ClassInhibitors
SystemCardiovascular, Blood
CompanyJanssen Pharmaceuticals
Approval Year2011

Indication

  • Indicated to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation
  • For thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure
  • For treatment of deep vein thrombosis (DVT)
  • For treatment of pulmonary embolism (PE)
  • For reduction in the risk of recurrence of DVT or PE
  • For the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery
  • For prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients
  • Indicated to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD)
  • Indicated to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD
  • For treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years
Last updated on 4/28/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Xarelto (rivaroxaban) Prescribing Information. 2022Janssen Ortho LLC Gurabo, PR
Document TitleYearSource
Efficacy of rivaroxaban in prevention of post-thrombotic syndrome: a systematic review and meta-analysis.2021Journal of Vascular Surgery: Venous and Lymphatic Disorders
Drug-drug interactions leading to adverse drug reactions with rivaroxaban: a systematic review of the literature and analysis of VigiBase. 2021Journal of Personalized Medicine
A comparison of aspirin against rivaroxaban for venous thromboembolism prophylaxis after hip or knee arthroplasty: a meta-analysis. 2020Journal of Orthopaedic Surgery
A systematic review of network meta-analyses and real-world evidence comparing apixaban and rivaroxaban in nonvalvular atrial fibrillation. 2020Clinical and Applied Thrombosis/Hemostasis
The safety and efficacy of rivaroxaban compared with warfarin in patients with atrial fibrillation and diabetes: a systematic review and meta-analysis.2020American Journal of Cardiovascular Drugs
Risk of post-thrombotic syndrome after deep vein thrombosis treated with rivaroxaban versus vitamin-K antagonists: a systematic review and meta-analysis.2020Thrombosis Research
Clinical effectiveness and safety of aspirin for venous thromboembolism prophylaxis after total hip and knee replacement. 2020JAMA
Economic evaluation of rivaroxaban versus enoxaparin for prevention of venous thromboembolism after total knee replacement and total hip replacement: a systematic review. 2020Clinical Drug Investigation
Efficacy and safety of low dose rivaroxaban in patients with coronary heart disease: a systematic review and meta-analysis. 2020Journal of Thrombosis and Thrombolysis
Efficacy and safety of non-vitamin K anticoagulants for atrial fibrillation in relation to different renal function levels: a network meta-analysis. 2020Cardiovascular Therapeutics
Risk of major gastrointestinal bleeding with new vs conventional oral anticoagulants: a systematic review and meta-analysis.2020Clinical Gastroenterology and Hepatology
Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation. 2020Circulation: Cardiovascular Quality and Outcomes
Efficacy and safety of direct oral anticoagulants in elderly patients with atrial fibrillation: a network meta-analysis. 2020Frontiers in Medicine
Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy.2020Cochrane Database of Systematic Reviews
Effectiveness and safety of rivaroxaban for the prevention of thrombosis following total hip or knee replacement: a systematic review and meta-analysis. 2019Medicine
Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world. 2019Blood Advances
Rivaroxaban versus aspirin in prevention of venous thromboembolism: a meta-analysis of 9 randomized controlled trials comprising 7,656 patients. 2019Stroke, Systemic or Venous Thromboembolism
A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation. 2019Nephrology Dialysis Transplantation
Medication adherence to rivaroxaban and dabigatran in patients with non-valvular atrial fibrillation: a meta-analysis. 2019Journal of Thrombosis and Thrombolysis
Oral anticoagulants in atrial fibrillation with valvular heart disease and bioprosthetic heart valves. 2019Heart
Venous thromboembolism prophylaxis strategies for people undergoing elective total knee replacement: a systematic review and network meta-analysis. 2019The Lancet Haematology
Venous thromboembolism prophylaxis strategies for people undergoing elective total hip replacement: a systematic review and network meta-analysis. 2019Value in Health
Safety and efficacy of direct acting oral anticoagulants and vitamin K antagonists in nonvalvular atrial fibrillation – a network meta-analysis of real-world data.2019VASA
Rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total knee arthroplasty. 2018Medicine
Meta-analysis of the safety and efficacy of the oral anticoagulant agents (apixaban, rivaroxaban, dabigatran) in patients with acute coronary syndrome. 2018The American Journal of Cardiology
Treatment for superficial thrombophlebitis of the leg. 2018Cochrane Database of Systematic Reviews
Systematic review and meta-analysis of real-world studies evaluating rivaroxaban for cancer-associated venous thrombosis. 2018Pharamacotherapy
Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. 2017BMJ
Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies. 2017Current Medical Research and Opinion
Effectiveness and safety of non-vitamin K antagonist oral anticoagulants for atrial fibrillation and venous thromboembolism: a systematic review and meta-analyses. 2017Clinical Therapeutics
Effects of non–vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta-analysis. 2017Journal of the American Heart Association
Safety and efficacy of new anticoagulants for the prevention of venous thromboembolism after hip and knee arthroplasty: a meta-analysis. 2017The Journal of Arthroplasty
Comparative efficacy and safety of anticoagulants for prevention of venous thromboembolism after hip and knee arthroplasty. 2017Acta Orthopaedica
Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. 2017Cochrane Database of Systematic Reviews
Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation. 2017Stroke
Comparison of the non-VKA oral anticoagulants apixaban, dabigatran, and rivaroxaban in the extended treatment and prevention of venous thromboembolism: systematic review and network meta-analysis.2016PLoS One